DE60137137D1 - Viren gegen hypoxische zellen und gewebe - Google Patents

Viren gegen hypoxische zellen und gewebe

Info

Publication number
DE60137137D1
DE60137137D1 DE60137137T DE60137137T DE60137137D1 DE 60137137 D1 DE60137137 D1 DE 60137137D1 DE 60137137 T DE60137137 T DE 60137137T DE 60137137 T DE60137137 T DE 60137137T DE 60137137 D1 DE60137137 D1 DE 60137137D1
Authority
DE
Germany
Prior art keywords
tissue
hypoxia
genes
operably linked
hypoxic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137137T
Other languages
German (de)
English (en)
Inventor
Meir Erwin Van
Ainsley C Nicholson
Dawn E Post
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE60137137D1 publication Critical patent/DE60137137D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60137137T 2000-09-26 2001-09-26 Viren gegen hypoxische zellen und gewebe Expired - Lifetime DE60137137D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23528300P 2000-09-26 2000-09-26
PCT/US2001/030236 WO2002026192A2 (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues

Publications (1)

Publication Number Publication Date
DE60137137D1 true DE60137137D1 (de) 2009-02-05

Family

ID=22884861

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137137T Expired - Lifetime DE60137137D1 (de) 2000-09-26 2001-09-26 Viren gegen hypoxische zellen und gewebe

Country Status (7)

Country Link
EP (1) EP1328291B1 (enExample)
JP (1) JP4709471B2 (enExample)
AT (1) ATE418342T1 (enExample)
AU (2) AU9479301A (enExample)
CA (1) CA2423833C (enExample)
DE (1) DE60137137D1 (enExample)
WO (1) WO2002026192A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501010A1 (en) * 2002-10-01 2004-04-15 Duke University Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
US20040142558A1 (en) 2002-12-05 2004-07-22 Granneman Ernst H. A. Apparatus and method for atomic layer deposition on substrates
US7601223B2 (en) 2003-04-29 2009-10-13 Asm International N.V. Showerhead assembly and ALD methods
US7537662B2 (en) 2003-04-29 2009-05-26 Asm International N.V. Method and apparatus for depositing thin films on a surface
US20080077999A1 (en) * 2004-03-23 2008-03-27 Eisai R&D Management Co., Ltd. Using Nonhuman Animal Model, Method of Measuring Transcription Activity Method of Measuring Cell Quantity and Method of Measuring Tumor Volume
US8487087B2 (en) 2005-03-11 2013-07-16 Oriental Yeast Co., Ltd. Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN116064675B (zh) * 2022-07-22 2024-12-03 西安电子科技大学 一种重组质粒、重组慢病毒载体、稳转细胞系及其构建方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783435A (en) * 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings
CA2308575A1 (en) * 1997-11-03 1999-05-14 Tom Tsang Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof

Also Published As

Publication number Publication date
WO2002026192A3 (en) 2002-08-08
EP1328291A4 (en) 2005-07-06
JP2004509635A (ja) 2004-04-02
AU9479301A (en) 2002-04-08
EP1328291B1 (en) 2008-12-24
JP4709471B2 (ja) 2011-06-22
EP1328291A2 (en) 2003-07-23
ATE418342T1 (de) 2009-01-15
WO2002026192A2 (en) 2002-04-04
AU2001294793B2 (en) 2006-06-29
CA2423833A1 (en) 2002-04-04
CA2423833C (en) 2011-02-22

Similar Documents

Publication Publication Date Title
ES2358204T3 (es) Adenovirus quiméricos para uso en el tratamiento del cáncer.
Mandelboim et al. NKp46
DE60323078D1 (de) Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
WO2004022716A3 (en) Recombinatant mutants of rhabdovirus and methods of use thereof
WO1999011764A3 (en) Methods for generating high titer helper-free preparations of recombinant aav vectors
DK1904635T3 (da) Glycosyleret IL-7, fremstilling og anvendelser
DE60137137D1 (de) Viren gegen hypoxische zellen und gewebe
ES2331441T3 (es) Dna que codifica dp-75 y un proceso para su uso.
JP4982680B2 (ja) デコリン遺伝子を含む薬剤学的抗腫瘍組成物
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
Jin et al. High-efficiency transduction and specific expression of ChR2opt for optogenetic manipulation of primary cortical neurons mediated by recombinant adeno-associated viruses
MX2022011805A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
JP2006523448A5 (enExample)
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
Bowden et al. Cells under siege: viral glycoprotein interactions at the cell surface
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
DE60237613D1 (de) Neue pgc-1-isoformen und deren verwendungen
AR025692A1 (es) VECTORES ADENOVIRALES RECOMBINANTES, UN PROCESO PARA SU MANUFACTURA, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO EN EL TRATAMIENTO DE DIVERSOS TIPOS DE FIBROSIS HEPÁTICA, RENAL, PULMONAR Y CICATRICES HIPERTROFICAS
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
US20110166207A1 (en) Use of aav integration efficiency element for mediating site-specific integration of a transcription unit
Smiben LeuSp DNA-binding domain-about turn!
Turner et al. Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart
KR100732248B1 (ko) ＶＥＧＦ 안티센스 ｃＤＮＡ를 함유하는 재조합아데노-연관 바이러스（ｒＡＡＶ）및 이를 함유하는 대장암및/또는 폐암 특이적 유전자 치료제
Plasschaert et al. A systemically delivered AAV-CFTR gene therapy for cystic fibrosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition